title: [Clinical use of virally inactived plasma. The experience of Blood Transfusion Unit in Mantova, Italy].
abstract: BACKGROUND
  Fresh Frozen Plasma (FFP) is a blood component whose clinical use is widespread worldwide. Transfusion safety of this product is ensured by legally obligatory tests. Although these tests are carried out on each plasma donation, safety levels can be further improved by using some technical procedures, such as, among others, methylene blue (MB) and solvent-detergent (SD) viral inactivation methods. The DMTE (Blood Transfusion Unit) in Mantova has used the pharmaceutical-like SD virally inactivated plasma since 2007 (Plasmasafe, Kedrion) as replacement of the PFC by each single donor. Guidelines for the usage of both products are the same.
  
  
  METHODS
  With the main aim of assessing the therapeutic effectiveness and safety of Plasmasafe, we decided to clinically monitor transfusions performed with this product on patients of the Intensive Care Unit at the city hospital in Mantova. In addition, we controlled some coagulation parameters (PT, aPTT, ATIII, Fibrinogen, PC, PS, FV, FVII, FVIII) before and 24 hours after the Plasmasafe infusion.
  
  
  RESULTS
  From a clinical point of view, the use of Plasmasafe always led to a significant reduction, or complete stop, of the bleeding. No transfusion-related adverse events were recorded. As regards, the most relevant laboratory results, a marked increase in the above mentioned hemostatic parameters was detected. Furthermore, patients transfused with this product received a mean volume significantly lower than an historical cohort of patients treated with FFP (503 mL with Plasmasafe versus 1549 mL with FFP, P<0.001).
  
  
  CONCLUSIONS
  The results of our study clearly document that Plasmasafe, a virally inactivated pharmaceutical-like product with a standardized content of coagulation factors, is a safe and cost-effective treatment, able to rapidly correct hemostatic abnormalities, for critical patients.
authors.forename: Debora
authors.initials: D
authors.lastname: Lepri
authors.forename: Enrico
authors.initials: E
authors.lastname: Capuzzo
authors.forename: Anna Vittoria
authors.initials: AV
authors.lastname: Mattioli
authors.forename: Daniela
authors.initials: D
authors.lastname: Dall'Oglio
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Sgarioto
authors.forename: Isabella
authors.initials: I
authors.lastname: Terenziani
authors.forename: Giacomo
authors.initials: G
authors.lastname: Caramaschi
authors.forename: Franco
authors.initials: F
authors.lastname: Manzato
authors.forename: Massimo
authors.initials: M
authors.lastname: Franchini
mesh_terms: D000368:Aged; D001779:Blood Coagulation Factors / Q000032:analysis; D016913:Blood Component Transfusion / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data*; D001798:Blood Proteins / Q000032:analysis; D058731:Blood Safety; D003902:Detergents; D005260:Female; D006470:Hemorrhage / Q000628:therapy; D006487:Hemostasis; D006801:Humans; D007558:Italy; D008297:Male; D010949:Plasma; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D012997:Solvents; D038301:Virus Inactivation
chemical_list: D001779:Blood Coagulation Factors; D001798:Blood Proteins; D003902:Detergents; D012997:Solvents